dm+d

73572009

Articles

Example medicines to prescribe by brand name in primary care

27 March 2022Prescribe certain medicines by brand to ensure supply of the same product. Examples are grouped by therapeutic area. The list of products is not exhaustive.

Supply and/or administration of Controlled Drugs under a Patient Group Direction

16 November 2021This Q&A summarises the legal position on the supply and/or administration of controlled drugs under PGDs.

Tool to calculate estimated dose equivalences of oral morphine to other oral opioids

14 September 2021Use our tool to obtain approximate dose equivalences of oral morphine to other oral opioids and help you calculate an estimated equivalent dose

Switching between oral morphine and other oral opioids in adult palliative cancer care patients

14 September 2021Switching between morphine and alternative opioids requires care and thoughtful application of a stepped process

How should medicines be dosed in children who are obese?

28 May 2021Review on how to calculate medicine doses in children who are obese which includes a table on commonly prescribed medicines.
Search Articles

Medicine Compliance Aid Stability

ZomorphArchimedes Pharma UK Ltd

Archimedes Pharma UK Ltd
Zomorph
Capsules m/r - various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Protect from moisture
Protect from heat
Protect from moisture and heat.
11 May 2015

SevredolNapp Pharmaceuticals Ltd

Napp Pharmaceuticals Ltd
Sevredol
Tablets f/c - various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light.
11 May 2015

Filnarine SRTeva Pharmaceuticals Ltd

Teva Pharmaceuticals Ltd
Filnarine SR
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
No special precautions for storage
No special precautions for storage.
11 May 2015

Morphgesic SRAmdipharm Mercury Co Ltd

Amdipharm Mercury Co Ltd
Morphgesic SR
Tablets f/c, m/r various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
Airtight container
Protect from light
Airtight container and protect from light.
11 May 2015

MST ContinusNapp Pharmaceuticals Ltd

Napp Pharmaceuticals Ltd
MST Continus
Tablets f/c, m/r various strengths
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Airtight container
Protect from light
Airtight container and protect from light
11 May 2015

MXLNapp Pharmaceuticals Ltd

Napp Pharmaceuticals Ltd
MXL
Capsules m/r - various strengths
A2 · Amber 2No stability data is available, the manufacturer does not, or cannot recommend use in CAs but there are no theoretical concerns with the product.
No special precautions for storage
No special precautions for storage
11 May 2015

Lactation Safety Information

Except for low dose, immediate release oral formulations

Except for low dose, immediate release oral formulations
Other appropriate analgesic
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Used in full-term neonates from birth
Infant monitoring advised, especially in young infants (see summary)
23 September 2020

Low dose, immediate release oral formulations

Low dose, immediate release oral formulations
Yes
Significant published evidence of use in breastfeeding
Small amounts in breast milk
Applies to short term, low dose (up to 10mg 4-hourly) oral solutions (e.g. Oramorph) and tablets
Although adverse effects in infant are not likely infant monitoring advised in young infants (see summary)
23 September 2020

New Medicines

ActimorphSevere pain which can only be managed with opioids, in adults and children aged 6 months and older - orodispersible formulation

Information

Actimorph
New formulation
Ethypharm
Not Known

Development and Regulatory status

Launched
None
None
April 2022
Apr 22Actimorph available in the UK. Price for a pack of 56: 1mg=£2.00; 2.5mg=£2.50; 5mg=£3.50; 10mg=£4.75; 20mg=£9.50; 30mg=£13.00.[4]
Mar 22Actimorph will be available in the UK from 1 May 2022 [3].
Jul 21MHRA approves Actimorph orodispersible tablets for severe pain which can be adequately managed only with opioids. Licensed for use in adults and children aged 6 months and older. An immediate-release formulation available in 1mg, 2.5mg, 5mg, 10mg, 20mg and 30mg strengths [2].

Category

An agonist at opiate receptors in the CNS particularly mu and to a lesser extent, kappa receptors. Mu receptors are thought to mediate supraspinal analgesia, respiratory depression and euphoria and kappa receptors, spinal analgesia, miosis and sedation. Formulated as an immediate-release orodispersible tablets and available in the following strengths: 1mg, 2.5mg, 5mg, 10mg, 20mg and 30mg.
Strong opioids such as morphine are useful for moderate-to-severe pain, particularly of visceral origin. Long-term prescribing is most common for palliative care in malignant disease but also may be appropriate for chronic non-malignant conditions, in conjunction with specialist advice. Long-term opioids have proved disappointing in the management of chronic non-cancer pain [1].
Severe pain which can only be managed with opioids, in adults and children aged 6 months and older - orodispersible formulation
Oral

Evidence based evaluations